Inflammation

The lack of effective long-term control of eosinophilic esophagitis (EoE) highlights the unmet need for targeted systemic therapies.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

The study was conducted because information on the relationship between eosinophilic esophagitis (EOE) symptoms and biologic findings are limited, so researchers looked at the long-term effects of esophageal dilation, including patient-reported outcome (PRO) measures.

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of comorbidities.

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.

Young adult men with chronic rhinosinusitis with nasal polyps were shown to be at greater risk of nasal polyp recurrence after endoscopic sinus surgery than elderly men and adult women of all ages.

A recent study found a correlation in patients with an IgE-mediated food allergy (IgE-FA) reporting symptoms of eosinophilic esophagitis (EoE), leading researchers to conclude screening for EoE may be beneficial.

A significantly greater proportion of patients with chronic rhinosinusitis with nasal polyps reported symptom-free days for at least 1 symptom when treated with dupilumab vs placebo in the 28 days preceding 24-week and 52-week analysis intervals.

Younger and older patients with noneosinophilic chronic rhinosinusitis (CRS) with nasal polyps showed significant differences in preoperative blood eosinophil levels and postoperative modified Lund-Kennedy scores.

A case report describes how an eosinophilic esophagitis diagnosis does not preclude other eosinophilic gastrointestinal diseases from developing.

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.

Patients with chronic rhinosinusitis (CRS) with nasal polyps exhibited significant improvement in olfactory function when treated with a combination of oral and nasal steroids vs nasal steroids alone.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.

FDA issued a complete response letter (CRL) to AstraZeneca seeking additional clinical data for benralizumab, sold as Fasenra, in the treatment of patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

Patients with chronic rhinosinusitis (CRS) with severe radiographic disease were more likely to report incidence of nasal polyps and be managed by endoscopic sinus surgery, but did not show greater health care utilization.

Administering dupilumab for other atopic conditions, including atopic dermatitis (AD) and asthma, in patients who also have eosinophilic esophagitis (EoE), resulted in improved EoE symptoms.

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have comorbidities were more likely than those without co-occuring conditions to require revision endoscopic sinus surgery over a 10-year period.

Eosinophilic esophagitis (EoE) has a psychological impact on children and families with the condition, says Colette Romero, who advocates for more awareness of the condition.

In Poland, the prevalence of chronic rhinosinusitis with nasal polyps was shown to be greater in men, elderly individuals, and those living in urban areas.

Abstracts presented at a recent meeting of allergists and immunologists explored early factors in disease development of eosinophilic esophagitis (EoE) as well as symptoms reported by parents and children.

The nasal polyposis quality of life (NPQ) questionnaire was shown to be valid, reliable, and sensitive to individual changes in evaluating the health-related quality of life of patients with chronic rhinosinusitis with nasal polyps.

During the annual meeting of the American Academy of Allergy, Asthma and Immunology, presenters said findings from a second phase 3 trial of dupilumab for eosinophilic esophagitis (EoE) continued to show the biologic improved symptoms in adults and adolescents.

Polyp recurrence occurred in more than 1 in 3 patients with chronic rhinosinusitis with nasal polyps who underwent endoscopic sinus surgery, with several prognostic factors linked with recurrence.

Patients with chronic rhinosinusitis (CRS) with nasal polyps reported significantly reduced anosmia prevalence when given dupilumab vs placebo.

Colette Romero, an advocate for eosinophilic esophagitis (EoE) awareness, discusses the steps her family went through to find a therapy plan that worked for her son.

Asthma, aspirin-exacerbated respiratory disease, and nasal cytology were identified as predictors of chronic rhinosinusitis with nasal polyps recurrence.

Eosinophilic esophagitis is a complex disorder with significant health burdens and a recent review described how management strategies have changed over time.

Diagnosis delays in eosinophilic esophagitis (EoE) are common, and Colette Romero's son had symptoms soon after birth but was not diagnosed until age 3.